{"id":52183,"date":"2026-07-10T14:01:18","date_gmt":"2026-07-10T14:01:18","guid":{"rendered":"https:\/\/www.europesays.com\/germany\/52183\/"},"modified":"2026-07-10T14:01:18","modified_gmt":"2026-07-10T14:01:18","slug":"pharmalittle-germany-wants-bigger-discounts-firms-embrace-secrecy","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/germany\/52183\/","title":{"rendered":"Pharmalittle: Germany wants bigger discounts, firms embrace secrecy"},"content":{"rendered":"<p>Good morning, everyone. Damian Garde here, filling in for Ed Silverman at Pharmalot\u2019s satellite campus along the East River, where today\u2019s cup of stimulation is filled not with coffee but rather a smoothie of curious color and questionable contents (what exactly is an \u201cadaptogen\u201d?). Anyway it\u2019s Friday, as you\u2019re almost certainly aware, and here are some tidbits to help you through the waning hours of another working week. \u2026<\/p>\n<p>German lawmakers passed a bill that would more than double the discount on branded medicines drugmakers must provide to the government, <a href=\"https:\/\/www.reuters.com\/business\/healthcare-pharmaceuticals\/germanys-lower-house-parliament-passes-healthcare-reform-2026-07-10\/\" target=\"_blank\" rel=\"noopener nofollow\">Reuters reports<\/a>. The policy, part of an effort to plug a sizable budget gap in the country\u2019s health insurance system, would increase the mandatory rebate from 7% to 15.5%. Industry groups have said the bill, if it clears Germany\u2019s upper chamber, would deter investment and imperil the country\u2019s access to new medicines.<\/p>\n<p>The rapid rise of China\u2019s biotech industry has led some American drug developers to do their work in near total secrecy, <a href=\"https:\/\/www.wsj.com\/tech\/biotech\/u-s-biotechs-are-keeping-more-secrets-to-beat-copycats-in-china-e2d62868?mod=hp_lead_pos4\" target=\"_blank\" rel=\"noopener nofollow\">the Wall Street Journal observes<\/a>. U.S. startups are increasingly loath to publish early data, disclose their scientific ambitions, or even publicize which diseases they hope to treat, all in fear that nimble Chinese firms will use that information to whip up competing drugs and beat them to the punch of starting clinical trials.<\/p>\n<p class=\"restricted-text\">STAT+ Exclusive Story<\/p>\n<p class=\"restricted-login\">Already have an account? <a href=\"https:\/\/www.statnews.com\/login\/\" data-stat-login=\"\" data-stat-paywall-cta=\"breaker login cta\" rel=\"nofollow noopener\" target=\"_blank\">Log in<\/a><\/p>\n<p>\t\t\t<img decoding=\"async\" class=\"restricted-content-breaker-bg\" src=\"https:\/\/www.europesays.com\/germany\/wp-content\/uploads\/2026\/05\/stat-plus-breaker-bg.png\" alt=\"STAT+\"\/><\/p>\n<p>\t\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" rel=\"nofollow noopener\" target=\"_blank\"><br \/>\n\t\t\t\t\t\t<img decoding=\"async\" class=\"stat-plus-logo\" src=\"https:\/\/www.statnews.com\/wp-content\/themes\/stat\/images\/stat-plus-logo-white.svg\" alt=\"STAT+\"\/><br \/>\n\t\t\t\t\t<\/a><\/p>\n<p>\t\t\t\tThis article is exclusive to STAT+ subscribers<br \/>\n\t\t\t\tUnlock this article \u2014 plus in-depth analysis, newsletters, premium events, and news alerts.<\/p>\n<p class=\"restricted-content-breaker-wrapper-cta mobile\">Already have an account? <a href=\"https:\/\/www.statnews.com\/login\/\" data-stat-login=\"\" data-stat-paywall-cta=\"breaker login cta mobile\" rel=\"nofollow noopener\" target=\"_blank\">Log in<\/a><\/p>\n<p>\t\t\t\t\t\tIndividual plans<\/p>\n<p>\t\t\t\t\t\tGroup plans<\/p>\n<p>\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" class=\"stat-button view-all\" data-stat-paywall-cta=\"breaker view all plans\" aria-label=\"View All Plans\" rel=\"nofollow noopener\" target=\"_blank\">View All Plans<\/a><\/p>\n<p class=\"restricted-content-text\">\n\t\t\t\t\t\tTo read the rest of this story subscribe to STAT+.\t\t\t\t\t<\/p>\n<p>\t\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" class=\"stat-button restricted-button\" data-stat-paywall-cta=\"breaker subscribe cta 1\" rel=\"nofollow noopener\" target=\"_blank\">Subscribe<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Good morning, everyone. Damian Garde here, filling in for Ed Silverman at Pharmalot\u2019s satellite campus along the East&hellip;\n","protected":false},"author":2,"featured_media":14410,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[5,18472,17988],"class_list":["post-52183","post","type-post","status-publish","format-standard","has-post-thumbnail","category-germany","tag-germany","tag-pharmalittle","tag-stat"],"_links":{"self":[{"href":"https:\/\/www.europesays.com\/germany\/wp-json\/wp\/v2\/posts\/52183","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/germany\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/germany\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/germany\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/germany\/wp-json\/wp\/v2\/comments?post=52183"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/germany\/wp-json\/wp\/v2\/posts\/52183\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/germany\/wp-json\/wp\/v2\/media\/14410"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/germany\/wp-json\/wp\/v2\/media?parent=52183"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/germany\/wp-json\/wp\/v2\/categories?post=52183"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/germany\/wp-json\/wp\/v2\/tags?post=52183"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}